Mamotest is the first FemTech in Latin America that universalizes access to breast studies to drastically reduce deaths from breast cancer. Its success in the province of Corrientes has been a fundamental block for understanding the high impact generated by access to mammograms in places where the system was not prepared for women’s health. Since 2013, the province has increased its capacity to prevent deaths from breast cancer six-fold.
“A technological system that provides early-stage breast cancer diagnoses also makes it possible to improve survival and reduce treatment costs; reducing poverty and inequality generated by failures in the health system ”, says Guillermo Pepe, founder of Mamotest. “The solutions that can demonstrate real changes in places as challenging as Latin America are the ones that pass the litmus test. If we can implement here, we can implement anywhere in the world ”, continues Pepe. This is a fundamental element for the most powerful investment groups in the world, who, within the framework of the Geneva Summit, meet every year to finance solutions that achieve the Sustainable Development Goals (SDGs).
The Sustainable Development Goals (SDGs)
On September 25, 2015, world leaders adopted a set of global goals to eradicate poverty, improve quality of life, protect the planet and ensure prosperity for all as part of a new sustainable development agenda. Each objective has specific goals that must be achieved in the next 15 years.
Importantly, of the 12 companies selected, 50 percent are run by women and 75 percent employ between 11 and 100 people. For this year, companies with themes of clean energy, access to quality health and waste management were chosen. Mamotest was selected in the health sector with the companies Livox (Brazil), Bempu Health (India) and Vula Mobile (South Africa), who will travel to Geneva, Switzerland, to present their projects to investors and find ways to scale these solutions at the level to achieve the goals of SDG 3: access to health.
These companies will speak at the United Nations headquarters in November. They will receive extensive exposure before and during the event, as well as access to a network of decision makers interested in learning more about their innovations and expansion plans. They will have a preparation program available and will benefit from a package of services provided by Summit partners.
The finalists represent $ 48 million in investment opportunities, impact the lives of 1.24 million people in need and serve 22,300 businesses, said Alessandra Rojas, manager of sustainable entrepreneurship at Epfl Tech4Impact. “The quality of the chosen companies is exceptional, they present strong business models and verified impact models,” said the manager. “This edition is a great success, as we received almost twice as many nominations as last year, which also shows the investment community’s appetite for sharing deals.”
Depending on the capital that is raised and the new partners, Mamotest seeks to expand its geographical position to implement the health technology solution starting in Latin America, to advance in vulnerable communities in the United States and Europe, Africa and then Asia. The good news is that the Mamotest system is very easy, fast and inexpensive to implement and does not require changes in hospital operations. Rather, it completely simplifies the breast cancer diagnosis process. A full implementation can take 48 hours, depending on the equipment that each hospital has. In addition, this network has a platform that allows doctors to carry out diagnoses in an effective way and consult among peers.
It is a meritorious recognition since the Mamotest centers were open throughout the strictest pandemic that the country experienced. The consultations remained between 60 and 75 percent, well above the average for the country. Rodrigo Villar Esquivel, Managing Partner of NV Group, who presented the company to the UN, comments “Mamotest is one of the best examples I have seen of social innovation. They have really managed to offer a solution to thousands of women to be able to detect cancer in early stages with affordable prices. Thanks to their innovative model, they have been able to scale profitably and save thousands of lives. “
–
